Platinum determination by inductively coupled plasma–sector field mass spectrometry (ICP–SFMS) in different matrices relevant to human biomonitoring
Authors:
- S. HannSHS. Hann
- G. KoellenspergerGKG. Koellensperger
- K. KanitsarKKK. Kanitsar
- G. StingederGSG. Stingeder
- M. BrunnerMBM. Brunner
- B. ErovicB. Erovic
- M. MüllerMMM. Müller
- 12 April 2003
- journal article
- research article
- Published by Springer Nature in Analytical and Bioanalytical Chemistry
- Vol. 376 (2) , 198-204
Abstract
The analytical challenges of Pt determination by ICP–SFMS posed by different human tissues and fluids have been critically assessed. Investigated samples were (1) urine, (2) serum of cancer patients sampled during chemotherapy with carboplatin, (3) microdialysates (20 µL sample volume) collected from tumor and non-tumor tissue, and, finally—for the first time—(4) human lung tissue to study background concentrations of inhaled platinum. Sample preparation involved microwave digestion and open vessel treatment or simple dilution (microdialysates). Depending on the sample preparation and introduction systems used (microconcentric nebulization, ultrasonic nebulization with and without membrane desolvation) excellent procedural detection limits (3s criterion) of 0.35 pg g−1 for urine, 420 pg g−1 for serum, 400 pg g−1 for lung tissue and 13 pg g−1 for microdialysates could be obtained. Ultratrace concentrations of 1–40 pg g−1, and 1000–3000 pg g−1 were measured in urine and human lung tissue, respectively, as typical for samples in environmental studies. Quantification was carried out by IDMS and standard addition in the case of urine samples. Internal standardization could not correct for non-spectral interferences in external calibration. In the serum and microdialysates of patients during chemotherapy with carboplatin, elevated Pt levels ranging between 0.01 and 10 µg g−1 were determined by external calibration (195Pt isotope). For all investigated samples spectral interferences could be excluded by following different strategies. High-resolution control measurements (194Pt, 195Pt) were performed in the case of elevated Pt levels, i.e. for microdialysates and serum samples. An Hf/Pt ratio of 0.4 was determined in human lung samples. An HfO formation ratio of 0.2% was assessed for standard solutions at the present experimental conditions, revealing that the contribution of 179Hf16O, 178Hf17O, 177Hf18O to the 195Pt isotope signal used for quantification was not significant.Keywords
This publication has 22 references indexed in Scilit:
- Science, medicine, and the future: MicrodialysisBMJ, 2002
- Determination of Rh, Pd and Pt in environmental silica containing matrices: capabilities and limitations of ICP-SFMSJournal of Analytical Atomic Spectrometry, 2000
- Platinum group metals (PGM); occurrence, use and recent trends in their determinationTrAC Trends in Analytical Chemistry, 2000
- Engine dynamometer experiments: platinum emissions from differently aged three-way catalytic convertersAtmospheric Environment, 1999
- Time-Dependent Increase of Traffic-Emitted Platinum-Group Elements (PGE) in Different Environmental CompartmentsEnvironmental Science & Technology, 1999
- Recent advances in the determination of the platinum group elements and goldTalanta, 1999
- Analytical problems in the determination of platinum-group metals in urine by quadrupole and magnetic sector field inductively coupled plasma mass spectrometryAnalytica Chimica Acta, 1998
- Determination of Physiological Palladium, Platinum, Iridium and Gold Levels in Human Blood Using Double Focusing Magnetic Sector Field Inductively Coupled Plasma Mass SpectrometryJournal of Analytical Atomic Spectrometry, 1997
- The determination of platinum in biological tissue by instrumental neutron activation analysisInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1991
- Determination of platinum in biotic and environmental materials part II: A sensitive voltammetric methodAnalytical and Bioanalytical Chemistry, 1989